1. Home
  2. YCBD vs APVO Comparison

YCBD vs APVO Comparison

Compare YCBD & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo cbdMD Inc.

YCBD

cbdMD Inc.

HOLD

Current Price

$0.79

Market Cap

7.9M

Sector

Health Care

ML Signal

HOLD

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$6.70

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YCBD
APVO
Founded
2015
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.9M
8.3M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
YCBD
APVO
Price
$0.79
$6.70
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$2.00
N/A
AVG Volume (30 Days)
572.6K
29.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,114,000.00
Revenue This Year
$3.88
N/A
Revenue Next Year
$10.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$0.25
52 Week High
$2.56
$13.11

Technical Indicators

Market Signals
Indicator
YCBD
APVO
Relative Strength Index (RSI) 43.85 47.21
Support Level $0.77 $6.12
Resistance Level $0.80 $7.70
Average True Range (ATR) 0.12 0.54
MACD 0.01 -0.03
Stochastic Oscillator 28.28 28.60

Price Performance

Historical Comparison
YCBD
APVO

About YCBD cbdMD Inc.

cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: